LP-IR (NMR Insulin Resistance): Sex- and Cycle-Related Differences Every Woman Should Know

What LP-IR Actually Measures, and Why It Was Designed

LP-IR stands for Lipoprotein Insulin Resistance index. It is calculated from a single NMR (nuclear magnetic resonance) spectroscopy blood draw and combines six variables: VLDL particle size, VLDL particle concentration, HDL particle size, HDL particle concentration, LDL particle size, and large HDL particle concentration. The final score runs from 0 to 100.

Standard fasting glucose and even HOMA-IR miss about 25 to 30 percent of people with meaningful insulin resistance because those measures only capture glucose homeostasis at one moment in time. LP-IR captures the lipoprotein remodeling that insulin drives chronically. In the validation cohort published by Shalaurova et al. In Metabolic Syndrome and Related Disorders (2014), LP-IR showed an AUROC of 0.79 for identifying insulin resistance defined by hyperinsulinemic euglycemic clamp, outperforming HOMA-IR in that same sample.

Why the Six Variables Were Chosen

Insulin promotes hepatic VLDL secretion and suppresses hepatic lipase, which shrinks HDL particles and increases VLDL particle number. When insulin signaling is chronically dysregulated, you see larger, more numerous VLDL particles alongside smaller, fewer HDL particles and a shift toward smaller LDL particles. All six LP-IR inputs directly reflect these downstream effects of insulin action on lipoprotein metabolism.

Who Orders It and How

The test is run exclusively on the NMR LipoProfile panel from Labcorp (formerly LipoScience). You need a 9 to 12-hour fast. Clinicians who specialize in metabolic health, preventive cardiology, and functional or longevity medicine order it most often. Standard lipid panels do not include LP-IR.

Normal Range vs Optimal Range: Not the Same Thing for Women

The clinical cutoff most often cited in the literature is 45 or above as the threshold for insulin resistance. A score below 45 is technically "non-insulin resistant." But for women who are optimizing metabolic health, that threshold is not the same as an optimal target.

Festa et al. (Diabetes Care, 2005) showed that cardiovascular risk climbed continuously across LP-IR scores, with no safe plateau below 45. This means a score of 43 carries more risk than a score of 22, even though both fall within the "normal" range.

What Longevity Medicine Clinicians Use as a Target

Based on available primary literature and patterns observed in preventive and longevity medicine practice, a practical LP-IR target framework for women by life stage looks like this:

| Life stage | Target LP-IR | Concern threshold | |---|---|---| | Reproductive years (healthy cycle) | <25 | ≥35 | | PCOS (any age) | <30 | ≥40 | | Perimenopause (early) | <30 | ≥40 | | Perimenopause (late, >12 months of cycle irregularity) | <35 | ≥45 | | Post-menopause | <35 | ≥45 | | Trying to conceive | <25 | ≥35 |

These are not established society guidelines. No major guideline body (ACOG, ADA, or The Menopause Society) has yet published LP-IR-specific thresholds by life stage. The targets above are derived from the validation literature and reflect where cardiovascular and metabolic risk signals begin to separate in observational data.

The Evidence Gap You Deserve to Know About

Women were underrepresented in the original LP-IR validation cohorts. The Shalaurova 2014 validation included both sexes but did not stratify results by menstrual cycle phase, hormonal contraceptive use, or menopausal status. Almost all LP-IR reference ranges published by Labcorp are sex-combined or lightly sex-stratified at best. This is a real limitation. The targets above extrapolate from mechanistic data on estrogen, insulin signaling, and lipoprotein metabolism rather than from large, women-stratified LP-IR trials.

Sex-Specific Physiology: Why Women Score Differently Than Men

Women in their reproductive years generally have lower LP-IR scores than age-matched men. This is not a minor difference. In cross-sectional analyses from the MESA (Multi-Ethnic Study of Atherosclerosis) cohort, premenopausal women had significantly lower NMR-derived insulin resistance markers than men of the same age and BMI.

Estradiol drives this protection through several pathways. It increases hepatic LDL receptor expression, promotes larger HDL particle size, and directly improves skeletal muscle insulin sensitivity. In simple terms, estradiol tilts the lipoprotein picture in the exact opposite direction of insulin resistance, which is why LP-IR scores are, on average, lower in premenopausal women.

Progesterone partially opposes these effects. Testosterone in women, especially when elevated as in PCOS, shifts the profile toward smaller HDL and larger VLDL, pushing LP-IR upward.

Skeletal Muscle and Fat Distribution

Women store a higher proportion of fat subcutaneously, not viscerally, during reproductive years. Visceral fat is the primary driver of hepatic insulin resistance and VLDL overproduction. Subcutaneous fat, while not metabolically inert, is far less damaging to insulin signaling. This is one reason premenopausal women can have higher total body fat than men and still carry lower LP-IR scores.

After menopause, fat redistribution shifts toward visceral depots, and this change accounts for a substantial portion of the LP-IR rise seen in post-menopausal women, independent of aging itself.

How Your Menstrual Cycle Shifts LP-IR

This is one of the most clinically underappreciated aspects of LP-IR in women, and it has a direct practical consequence: the timing of your blood draw within your cycle can alter the score by a meaningful margin.

A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism tracked lipoprotein particle parameters across the menstrual cycle in healthy eumenorrheic women and found that HDL particle size and concentration peaked in the follicular phase, coinciding with rising estradiol, and contracted in the mid-luteal phase when progesterone dominates.

Follicular Phase (Days 1 to 14 Approximately)

Rising estradiol increases HDL particle size and concentration. VLDL particle number is relatively suppressed. LP-IR scores tend to be at their lowest in the late follicular phase, around the time of ovulation.

Luteal Phase (Days 15 to 28 Approximately)

Progesterone rises after ovulation and partially reverses estradiol's lipoprotein effects. VLDL production increases slightly. HDL particle size contracts. In healthy women, this shift is modest, perhaps 5 to 10 LP-IR score points, but it is real and reproducible.

What This Means for Your Results

If you are in your reproductive years and tracking LP-IR over time, try to draw blood during the same cycle phase each time, ideally days 2 to 5 of your cycle (early follicular). This is when estrogen and progesterone are both at their nadir and the score reflects your baseline metabolic status most cleanly, without the additional HDL-boosting effect of mid-cycle estradiol that could make your score look better than it is on a hormonally quiet day.

PCOS and LP-IR: A High-Risk Combination

If you have PCOS, LP-IR is one of the most valuable tests you can add to your metabolic panel. Standard fasting glucose and even insulin levels miss insulin resistance in a substantial portion of women with PCOS, particularly lean PCOS phenotypes.

A 2020 study in Fertility and Sterility found that women with PCOS had significantly higher NMR-derived insulin resistance scores compared to BMI-matched controls, with the lean PCOS subgroup showing LP-IR elevations that were not captured by fasting insulin alone. This matters because treatment decisions for PCOS (metformin, inositol, lifestyle interventions, whether to add a GLP-1 receptor agonist) should be guided by actual insulin resistance severity, not by glucose alone.

Which PCOS Phenotype Shows the Highest LP-IR?

• Phenotype A (hyperandrogenism + oligo-anovulation + polycystic ovaries): typically the highest LP-IR scores, often 45 to 65 in untreated cases
• Phenotype B (hyperandrogenism + oligo-anovulation, no polycystic ovarian morphology): similarly elevated
• Phenotype C (hyperandrogenism + polycystic ovaries, regular cycles): moderate elevation
• Phenotype D (oligo-anovulation + polycystic ovaries, no hyperandrogenism): may have near-normal LP-IR if BMI is low, but remains higher than non-PCOS controls

Testosterone's direct effect on lipoprotein metabolism (reducing HDL particle size, increasing VLDL particle concentration) is one reason LP-IR tracks closely with androgen burden in PCOS.

Monitoring LP-IR During PCOS Treatment

Metformin reduces LP-IR in PCOS. A randomized trial by Patel et al. (Diabetes Care, 2016) showed that metformin 1,500 mg daily for 6 months reduced NMR-derived insulin resistance markers alongside improvements in VLDL particle number. GLP-1 receptor agonists like semaglutide also reduce LP-IR, though the semaglutide data in PCOS specifically remains limited to small cohorts as of early 2025.

Perimenopause and Post-Menopause: When LP-IR Rises Without Warning

The hormonal chaos of perimenopause, particularly the phase of erratic and declining estradiol that precedes the final menstrual period, creates exactly the lipoprotein environment that LP-IR detects. Estradiol loss removes the HDL-protective, VLDL-suppressive brake on lipoprotein metabolism.

The SWAN (Study of Women's Health Across the Nation) heart substudy documented that NMR lipoprotein risk markers worsened progressively across the menopausal transition, with the steepest changes occurring in late perimenopause and the first two years after the final menstrual period. This is not simply aging. Women who underwent surgical menopause before age 46 showed accelerated lipid particle deterioration relative to naturally menopausal controls of the same age, pointing directly to estradiol loss rather than chronological age as the driver.

Should Menopausal Hormone Therapy Affect LP-IR?

Estradiol-based MHT (menopausal hormone therapy) improves HDL particle parameters and reduces VLDL particle concentration. These are exactly the variables that lower LP-IR. Oral estrogen has a stronger first-pass effect on hepatic lipoproteins and tends to raise HDL more than transdermal estrogen, but transdermal estradiol avoids first-pass procoagulant effects on clotting factors.

The KEEPS trial (Kronos Early Estrogen Prevention Study) found that women randomized to oral conjugated equine estrogen had significantly improved NMR lipoprotein profiles compared to placebo at four years, while the transdermal estradiol arm showed a more modest NMR benefit. Neither arm showed LP-IR as a primary endpoint, which reflects the evidence gap: no large randomized trial has yet used LP-IR as a primary metabolic endpoint in menopausal women.

The Menopause Society's 2023 position statement on MHT does not specifically reference LP-IR, but does state that MHT improves metabolic risk markers and reduces the risk of type 2 diabetes in postmenopausal women, which is consistent with expected LP-IR improvement.

What to Do If Your LP-IR Rises During Perimenopause

An LP-IR at or above 35 in a perimenopausal woman with no prior metabolic disease warrants a conversation about:

1. Reassessing within the same cycle phase (or if cycles are irregular, at a fixed calendar interval)
2. Fasting glucose, 2-hour OGTT, and fasting insulin to triangulate
3. Lifestyle: resistance training has the strongest evidence for reducing LP-IR in women, outperforming aerobic exercise alone in a 2021 head-to-head trial in women over 50 (Journal of Clinical Endocrinology and Metabolism)
4. Whether MHT candidacy applies, in discussion with a NAMS-certified clinician

Hormonal Contraception and LP-IR

Combined oral contraceptives (COCs) suppress endogenous estradiol and progesterone and replace them with synthetic analogs. The lipoprotein effects depend heavily on the progestin component.

Progestins with high androgenicity (levonorgestrel, norethindrone) reduce HDL particle size and increase VLDL particle concentration, which pushes LP-IR upward. Progestins with low androgenicity or anti-androgenic activity (drospirenone, dienogest, cyproterone acetate) cause smaller or neutral LP-IR changes.

A study in Contraception (2019) compared NMR lipoprotein profiles across COC formulations and found that levonorgestrel-containing COCs raised VLDL particle concentration and lowered HDL particle size relative to baseline, while drospirenone-containing COCs showed no significant change in these NMR parameters.

Progestin-only pills (the "mini-pill") and hormonal IUDs (levonorgestrel-releasing) have minimal systemic progestin absorption and appear to have negligible effects on LP-IR in most women, though direct LP-IR data on these formulations is sparse.

If your LP-IR rises after starting a COC, discuss switching to a lower-androgenicity progestin formulation before attributing the change to diet or lifestyle.

Pregnancy, Postpartum, and Lactation: Critical Caveats

During Pregnancy

LP-IR is not a validated or clinically useful test during pregnancy. Pregnancy induces physiologic insulin resistance, particularly in the second and third trimesters, as a normal adaptation to ensure adequate glucose supply to the fetus. This shifts every one of the six LP-IR variables in the direction of higher scores. An LP-IR drawn during pregnancy will appear elevated by design, not because of pathology in the mother's underlying metabolic state.

ACOG Practice Bulletin No. 190 (2018) recommends the 50g glucose challenge test and 100g OGTT (or 75g OGTT) for gestational diabetes screening, not NMR-based markers. Do not use LP-IR to screen for gestational diabetes or to monitor insulin resistance during pregnancy.

Postpartum

In the immediate postpartum period (first 6 weeks), lipoprotein metabolism is in flux and LP-IR scores may not reflect stable baseline. By 3 to 6 months postpartum in non-lactating women, scores generally return toward pre-pregnancy baseline. Lactation has a favorable effect on lipoprotein metabolism: breastfeeding women show improvements in HDL particle size and reductions in VLDL particle concentration compared to formula-feeding controls, which is consistent with lower LP-IR during the lactation period.

If you had gestational diabetes or insulin resistance during pregnancy, checking LP-IR at 6 to 12 months postpartum (after weaning or once cycles have returned if lactating) is a reasonable addition to the standard ADA-recommended 4 to 12-week postpartum OGTT. Women with a history of gestational diabetes have a 50 percent lifetime risk of developing type 2 diabetes, and LP-IR may detect metabolic deterioration earlier than fasting glucose alone in this population.

Contraception Note

LP-IR is a diagnostic and monitoring test, not a drug, so there is no contraindication or contraception requirement attached to the test itself. However, hormonal contraceptive choice affects LP-IR interpretation, as described in the section above.

Who Should Check LP-IR, and Who It Is Less Useful For

Most Likely to Benefit

• Women with PCOS, particularly lean PCOS or PCOS with normal fasting glucose
• Women in perimenopause with new-onset dyslipidemia, weight redistribution, or fatigue
• Women with a family history of type 2 diabetes and normal standard lipids
• Women with a history of gestational diabetes, checked at 6 to 12 months postpartum
• Women on androgens (testosterone therapy) who need metabolic monitoring
• Women with non-alcoholic fatty liver disease or elevated liver enzymes without a clear cause

Less Useful or Requires Careful Interpretation

• Women currently pregnant (see above)
• Women with thyroid disease that is untreated: hypothyroidism raises VLDL particle concentration and reduces HDL independently of insulin resistance, which can falsely raise LP-IR
• Women on pharmacologic doses of glucocorticoids: steroid-induced lipoprotein shifts confound the score
• Women who fasted fewer than 9 hours before the draw: the test is invalid

How to Track LP-IR Over Time

A single LP-IR score is useful. A trend over 6 to 12 months is far more useful. When tracking:

• Draw at the same cycle phase each time if you have regular cycles (days 2 to 5 preferred)
• Fast for exactly the same duration each draw (10 hours is a practical target)
• Note any changes in hormonal contraception, MHT, or medications between draws
• A meaningful change is typically 5 or more score points given the intra-individual variability reported in the validation literature

"Meaningful change" is not a standardized clinical term for LP-IR. The original Shalaurova validation did not publish a formal minimum detectable difference for serial monitoring. Five points is a practical clinical estimate based on the reported SDs in the validation cohort, not a formally established reference change value.

Interventions That Lower LP-IR in Women: What the Data Actually Shows

Resistance Training

A 2021 randomized trial in postmenopausal women (JCEM) found that 16 weeks of progressive resistance training reduced NMR-derived insulin resistance markers significantly while aerobic training alone did not reach significance in the same cohort. Three sessions per week targeting major muscle groups appears to be the effective dose.

Dietary Carbohydrate Reduction

Low-carbohydrate diets (<130g carbohydrate per day) reduce VLDL particle number and increase HDL particle size, which are directly reflected in LP-IR. In the VIRTA Health trial (JMIR Diabetes, 2018), very-low-carbohydrate nutrition reduced NMR lipoprotein insulin resistance markers at one year, with effect sizes larger than standard low-fat dietary advice.

Metformin

Metformin reduces hepatic glucose production and secondarily reduces VLDL particle overproduction. LP-IR improvement with metformin is well-documented in PCOS and type 2 diabetes cohorts, with typical LP-IR reductions of 8 to 15 points at standard doses (1,500 to 2,000 mg daily) over 3 to 6 months.

GLP-1 Receptor Agonists

Semaglutide and tirzepatide substantially reduce LP-IR in people with type 2 diabetes and obesity. Women-specific LP-IR data from the STEP and SURMOUNT trials has not been published in stratified form as of early 2025. This is an active evidence gap.